Tag: antiStaphylococcus
PHAXIAM Therapeutics announces a high level of performance of its two anti-Staphylococcus aureus phages on clinical strains – 10/09/2023 at 10:05 p.m.
Data obtained from the phagogram developed by PHAXIAM, the first phage sensitivity test with CE marking, showed a response rate of 98% on 105 clinical strains of S. aureus. Lyon…
PHAXIAM Therapeutics announces a high level of performance of its two anti-Staphylococcus aureus phages on clinical strains – 10/09/2023 at 10:05 p.m.
PHAXIAM Therapeutics announces a high level of performance of its two anti- Staphylococcus aureus on clinical strains Data obtained from the phagogram developed by PHAXIAM, the first phage sensitivity test…
Pherecydes Pharma obtains Compassionate Access Authorization (AAC) from the ANSM for its anti-Staphylococcus aureus phages – 05/30/2022 at 18:00
Frédérique Vieville, Quality Director of Pherecydes Pharma, comments: “We are proud to be one of the very first French companies to obtain compassionate access authorization, associated with a Temporary Use…